G1 Therapeutics (GTHX)
(Delayed Data from NSDQ)
$3.72 USD
-0.27 (-6.77%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $3.72 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value A Growth B Momentum C VGM
Income Statements
Fiscal Year end for G1 Therapeutics falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 83 | 51 | 31 | 45 | 0 |
Cost Of Goods | 7 | 4 | 2 | 0 | 0 |
Gross Profit | 75 | 48 | 29 | 45 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 115 | 184 | 172 | 142 | 129 |
Income After Depreciation & Amortization | -40 | -136 | -142 | -96 | -129 |
Non-Operating Income | 5 | 1 | 0 | 0 | 7 |
Interest Expense | 10 | 10 | 5 | 2 | 0 |
Pretax Income | -45 | -146 | -147 | -98 | -122 |
Income Taxes | 3 | 2 | 1 | 1 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -48 | -148 | -148 | -99 | -122 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -48 | -148 | -148 | -99 | -122 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -38 | -133 | -141 | -95 | -129 |
Depreciation & Amortization (Cash Flow) | 2 | 3 | 2 | 1 | 0 |
Income After Depreciation & Amortization | -40 | -136 | -142 | -96 | -129 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 51.73 | 43.63 | 41.94 | 37.88 | 37.50 |
Diluted EPS Before Non-Recurring Items | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 |
Diluted Net EPS (GAAP) | -0.93 | -3.38 | -3.54 | -2.62 | -3.27 |
Fiscal Year end for G1 Therapeutics falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 14.87 | 12.30 | 42.39 | 12.95 |
Cost Of Goods | NA | 1.26 | 3.08 | 1.40 | 1.46 |
Gross Profit | NA | 13.62 | 9.22 | 40.99 | 11.49 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 22.55 | 25.59 | 29.47 | 37.23 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -8.93 | -16.37 | 11.52 | -25.74 |
Non-Operating Income | NA | 2.25 | 1.18 | 1.21 | 1.24 |
Interest Expense | NA | 2.12 | 2.12 | 2.71 | 3.09 |
Pretax Income | NA | -9.98 | -17.30 | 10.02 | -27.60 |
Income Taxes | NA | 0.90 | 0.91 | 1.31 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -10.88 | -18.20 | 8.71 | -27.60 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -10.88 | -18.20 | 8.71 | -27.60 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 51.84 | 51.78 | 61.04 | 51.65 |
Diluted EPS Before Non-Recurring Items | NA | -0.21 | -0.35 | 0.14 | -0.53 |
Diluted Net EPS (GAAP) | NA | -0.19 | -0.35 | 0.14 | -0.53 |